Megan Brooks The US Food and Drug Administration (FDA) has approved crizanlizumab (Adakveo, Novartis) to reduce the frequency of vaso-occlusive crisis in patients aged 16 years or older with sickle cell disease. “Vaso-occlusive crisis can be extremely painful and is a frequent reason for emergency department visits and hospitalization for patients with sickle cell disease,”...
Tag: <span>Sickle Cell Crisis</span>
Post
FDA OKs Crizanlizumab, First Targeted Therapy for Sickle Cell Crisis
Megan Brooks The US Food and Drug Administration (FDA) has approved crizanlizumab (Adakveo, Novartis) to reduce the frequency of vaso-occlusive crisis in patients aged 16 years or older with sickle cell disease. “Vaso-occlusive crisis can be extremely painful and is a frequent reason for emergency department visits and hospitalization for patients with sickle cell disease,” Richard Pazdur, MD,...